Repligen Corporation: financial analysis
Ratios worked out from 10 fiscal years of Repligen Corporation's statements, compared with 53 companies in Medical Instruments.
Repligen Corporation scorecard#
Passes 11 of the 26 checks that could be worked out: strongest in financial health (5 of 6), weakest in valuation (0 of 6). Fiscal year 2025; market cap of Oct 27, 2026.
Valuation0 of 6
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median5.5×Price to book 5.5× against Medical Instruments's median of 3.9×.
- ✗Price to sales below its peers' median14.3×Price to sales 14.3× against Medical Instruments's median of 3.0×.
- ✗Free cash flow yield above 5%0.8%Free cash flow is 0.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- ✗The price assumes slower growth than the last three years'30.7%The price assumes 30.7% a year for ten years; revenue grew -2.7% a year over the last three.
Growth3 of 6
- ✓Revenue grew in the newest year16.4%Revenue up 16.4% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-2.7%-2.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-2.7%-2.7% a year against Medical Instruments's median of 5.0% (37 companies).
- ✓Earnings per share grew in the newest year0.86 vs -0.46Diluted EPS 0.86 in fiscal 2025 against -0.46 the year before (report's currency).
- ✗Net income higher than five years earlier$49 M$49 M in fiscal 2025 against $60 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability2 of 6
- ✓Profitable in the newest year$49 MNet income $49 M in fiscal 2025.
- ✗Profitable in each of the last five years4 of 5Profitable in 4 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median7.5%7.5% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%2.4%2.4% in fiscal 2025.
- ✗Return on invested capital above 10%2.3%2.3% in fiscal 2025.
- ✗Operating margin wider than three years earlier7.5%7.5% in fiscal 2025 against 28.0% in 2022.
Financial health5 of 6
- ✓Short-term assets cover short-term liabilities8.4×Current ratio 8.37 at the end of fiscal 2025.
- ✓Debt below equity0.3×Debt to equity 0.26 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $24 M at the end of fiscal 2025.
- ✗Operating income covers interest five times2.4×Operating income 2.4 times interest in fiscal 2025.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone9.13Z-score 9.13 (safe zone) for fiscal 2025.
Shareholder returns1 of 2
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.8%Diluted shares up 1.8% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Free cash flow has been positive 14 years in a row.
- More cash than debt: net cash of $24 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsyes
- Current ratio roseno
- No new shares issuedno
- Gross margin roseyes
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.34 | × 1.2 | 0.41 |
| Retained earnings to assets | 0.15 | × 1.4 | 0.22 |
| Operating income to assets | 0.02 | × 3.3 | 0.06 |
| Market value to liabilities | 13.65 | × 0.6 | 8.19 |
| Revenue to assets | 0.25 | × 1 | 0.25 |
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.3% | 43.3% | 44.0% | 56.9% | 58.4% | 56.2% | 30% | |
| Operating margin | 7.5% | -5.5% | 7.5% | 28.0% | 24.9% | 7.2% | 51% | |
| Net margin | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 3.8% | 61% | |
| Return on equity | 2.4% | -1.3% | 1.8% | 10.2% | 7.8% | 3.5% | 49% | |
| Return on assets | 1.7% | -0.9% | 1.3% | 7.6% | 6.0% | 1.3% | 51% | |
| Return on invested capital | 2.3% | — | — | — | — | 8.7% | 9% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 16.4% | 0.3% | -21.1% | 19.5% | 83.1% | 8.9% | 73% | |
| Revenue growth, 3 years a year | -2.7% | -1.8% | 20.0% | 43.7% | 51.2% | 5.0% | 19% | |
| Revenue growth, 5 years a year | 15.1% | 18.6% | 26.7% | 41.5% | 45.0% | 8.9% | 75% | |
| Net income growth | — | — | -80.9% | 45.0% | 114.1% | 8.8% | — | |
| Earnings per share growth | — | — | -80.6% | 44.6% | 101.8% | 7.2% | — |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.26× | 0.27× | — | — | — | 0.46× | 70% | |
| Net debt | $-24 M | $-232 M | — | — | — | $169 M | 81% | |
| Net debt to EBITDA | -0.18× | -6.71× | — | — | — | 0.82× | 85% | |
| Interest cover | 2.44× | -1.61× | 24.46× | 193.68× | 14.83× | 2.44× | 50% | |
| Current ratio | 8.37× | 8.41× | 6.74× | 2.47× | 2.48× | 2.99× | 89% | |
| Equity share of assets | 71.4% | 69.7% | 69.4% | 75.5% | 74.2% | 57.0% | 71% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $94 M | $150 M | $78 M | $87 M | $52 M | $25 M | 68% | |
| Free cash flow margin | 12.7% | 23.6% | 12.3% | 10.9% | 7.7% | 6.3% | 68% | |
| Cash conversion | 240.2% | — | 320.0% | 92.5% | 92.8% | 204.4% | 75% | |
| Capital spending share of revenue | 3.2% | 4.1% | 5.7% | 10.6% | 10.0% | 2.6% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.26× | 0.22× | 0.24× | 0.33× | 0.31× | 0.55× | 9% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Return on invested capital
- Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Net debt to EBITDA
- Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).